MEDIFIC INC.

Booth 2464
Hwaseong-si, Korea, Republic of
MEDIFC Inc. is a biotechnology company based in Korea devoted to developing first-in-class anti-cancer drugs to target cancer stem cell.

About MEDIFIC Inc.

MEDIFIC is a pre-clinical stage biotech company developing first-in-class anti-cancer drugs to target cancer stem cells (CSCs). MEDIFIC was founded in 2018, based on expertise in brain cancer and CSC research for over 20 years from academia (Korea University). MEDIFIC is dedicated to developing innovative anti-cancer drugs that can provide a better therapeutic opportunity to patients suffering from malignant cancers, especially glioblastoma (GBM) and intractable diseases.
MEDIFIC takes an open innovation strategy to collaborate with expert groups in a variety of fields, such as biology, pharmacology, medicinal chemistry, clinical medicine, and business development. MEDIFIC has signed a joint research contract with Korea University, Seoul National University and Chungbuk National University, and MOU for collaboration with KMEDI hub.
MEDIFIC was selected for a non-clinical development project from Korea Drug Development Fund (KDDF; 2022) and an Innovative Startup Project from the Ministry of SMEs and Startups of Korea (2023).

Our Professionality
■ Discovery and validation of pharmacological target for the CSC-targeted therapy
■ Hit discovery and lead optimization of small molecule drugs
■ Drug screening system to validate the efficacy and MoA for innovative but undruggable target proteins
■ In vivo evaluation of PK/PD using the GBM orthotopic xenograft mouse model and solid tumor SC xenograft mouse model.
Focus Areas